Advanced search
1 file | 764.04 KB

Biodistribution and tolerance of intravenous iodine-131-labelled hypericin in healthy dogs

Eline Abma (UGent) , Kathelijne Peremans (UGent) , Filip De Vos (UGent) , Tim Bosmans (UGent) , Adriaan Kitshoff (UGent) , Sylvie Daminet (UGent) , Y Ni, Robrecht Dockx (UGent) and Hilde De Rooster (UGent)
Author
Organization
Abstract
Hypericin (Hyp) is a necrosis-avid compound that can be efficiently labelled with radioiodine for both diagnostic and therapeutic purposes. Before I-131-Hyp can be considered as a clinically useful drug in a combination therapy for canine cancer patients, evaluation of its toxicity is necessary. The aim of this study was to investigate the biodistribution and tolerance of a single dose administration of I-131-Hyp. Three healthy dogs were included. I-131-Hyp at a dose of 0.2 mg/kg and an activity of 185 MBq was intravenously injected. The effects on physical, haematological and biochemical parameters were characterized and the biodistribution and elimination pattern, the effective half-life and dose rate were assessed. Drug-related adverse events were limited to mild gastrointestinal signs, resolving within 48 hours. No significant differences were found in blood haematology and serum biochemistry before and after treatment. Following administration, highest percentage of injected dose (%ID +/- SD) was found in the liver (5.5 +/- 0.33), the lungs (4.17 +/- 0.14) and the heart (3.11 +/- 0.78). After 24 hours, highest %ID was found in colon (4.25 +/- 1.45) and liver (3.45 +/- 0.60). Clearance from all organs was effective within 7 days. Effective half-life was established at 80 hours, and the dose rate fell below <20 Sv/h at 1 m within 1 day. The current study reveals that single dose treatment with I-131-Hyp at the described dose is well tolerated by healthy dogs and supports the use of radioiodinated hypericin in a combination therapy for canine cancer patients.
Keywords
dog, hypericin, iodine-131, radionuclide cancer therapy, targeted tumour radiotherapy, NECROSIS TARGETED RADIOTHERAPY, COMBRETASTATIN A4 PHOSPHATE, ST-JOHNS-WORT, RADIOIODINATED HYPERICIN, DIMETHYL-SULFOXIDE, CANCER-THERAPY, MOUSE MODEL, TUMOR, AGENT, PHARMACOKINETICS

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 764.04 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Abma, Eline, Kathelijne Peremans, Filip De Vos, Tim Bosmans, Adriaan Kitshoff, Sylvie Daminet, Y Ni, Robrecht Dockx, and Hilde De Rooster. 2018. “Biodistribution and Tolerance of Intravenous Iodine-131-labelled Hypericin in Healthy Dogs.” Veterinary and Comparative Oncology 16 (3): 318–323.
APA
Abma, Eline, Peremans, K., De Vos, F., Bosmans, T., Kitshoff, A., Daminet, S., Ni, Y., et al. (2018). Biodistribution and tolerance of intravenous iodine-131-labelled hypericin in healthy dogs. VETERINARY AND COMPARATIVE ONCOLOGY, 16(3), 318–323.
Vancouver
1.
Abma E, Peremans K, De Vos F, Bosmans T, Kitshoff A, Daminet S, et al. Biodistribution and tolerance of intravenous iodine-131-labelled hypericin in healthy dogs. VETERINARY AND COMPARATIVE ONCOLOGY. 2018;16(3):318–23.
MLA
Abma, Eline, Kathelijne Peremans, Filip De Vos, et al. “Biodistribution and Tolerance of Intravenous Iodine-131-labelled Hypericin in Healthy Dogs.” VETERINARY AND COMPARATIVE ONCOLOGY 16.3 (2018): 318–323. Print.
@article{8560598,
  abstract     = {Hypericin (Hyp) is a necrosis-avid compound that can be efficiently labelled with radioiodine for both diagnostic and therapeutic purposes. Before I-131-Hyp can be considered as a clinically useful drug in a combination therapy for canine cancer patients, evaluation of its toxicity is necessary. The aim of this study was to investigate the biodistribution and tolerance of a single dose administration of I-131-Hyp. Three healthy dogs were included. I-131-Hyp at a dose of 0.2 mg/kg and an activity of 185 MBq was intravenously injected. The effects on physical, haematological and biochemical parameters were characterized and the biodistribution and elimination pattern, the effective half-life and dose rate were assessed. Drug-related adverse events were limited to mild gastrointestinal signs, resolving within 48 hours. No significant differences were found in blood haematology and serum biochemistry before and after treatment. Following administration, highest percentage of injected dose (\%ID +/- SD) was found in the liver (5.5 +/- 0.33), the lungs (4.17 +/- 0.14) and the heart (3.11 +/- 0.78). After 24 hours, highest \%ID was found in colon (4.25 +/- 1.45) and liver (3.45 +/- 0.60). Clearance from all organs was effective within 7 days. Effective half-life was established at 80 hours, and the dose rate fell below {\textlangle}20 Sv/h at 1 m within 1 day. The current study reveals that single dose treatment with I-131-Hyp at the described dose is well tolerated by healthy dogs and supports the use of radioiodinated hypericin in a combination therapy for canine cancer patients.},
  author       = {Abma, Eline and Peremans, Kathelijne and De Vos, Filip and Bosmans, Tim and Kitshoff, Adriaan and Daminet, Sylvie and Ni, Y and Dockx, Robrecht and De Rooster, Hilde},
  issn         = {1476-5810},
  journal      = {VETERINARY AND COMPARATIVE ONCOLOGY},
  language     = {eng},
  number       = {3},
  pages        = {318--323},
  title        = {Biodistribution and tolerance of intravenous iodine-131-labelled hypericin in healthy dogs},
  url          = {http://dx.doi.org/10.1111/vco.12381},
  volume       = {16},
  year         = {2018},
}

Altmetric
View in Altmetric
Web of Science
Times cited: